Free Trial
ASX:EMD

Emyria (EMD) Stock Price, News & Analysis

Emyria logo

About Emyria Stock (ASX:EMD)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
471,333 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson's disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the advancement of Emyria's MDMA analogue drug development program, targeting mental health and neurodegenerative diseases, including Parkinson's. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was incorporated in 2018 and is headquartered in Leederville, Australia.

Receive EMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emyria and its competitors with MarketBeat's FREE daily newsletter.

EMD Stock News Headlines

Emyria Limited Plans Major Securities Issuance
Could This Tiny Device Help You Make an Extra $30k a Year?
I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.
Emyria Limited Announces Successful AGM Resolutions
Emyria Ltd Announces Key Growth and Innovation Milestones
See More Headlines

EMD Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Emyria investors own include AGNC Investment (AGNC), Ashford Hospitality Trust (AHT), Allakos (ALLK), Alpine Summit Energy Partners (ALPS), Brookfield Infrastructure Partners (BIP), BioXcel Therapeutics (BTAI) and Carador Income Fund (CIF).

Industry, Sector and Symbol

Sector
Medical
Industry
Health Information Services
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-11,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.20 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.81
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (ASX:EMD) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners